While PI3K gain-of-function mutations were detected in 25% of patients suffering from glioblastoma, the main negative regulator of the PI3K/AKT/mTOR pathway, the phosphatase and tensin homolog (PTEN), is deleted or affected by loss-of-function mutations in 40% of the cases. Here, MTOR is linked to glioblastoma.